Vanguard Fiduciary Trust
CSTL icon

Vanguard Fiduciary Trust’s Castle Biosciences CSTL Stock Holding History

Vanguard Fiduciary Trust’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.71M Buy
197,494
+9,283
+5% +$207K ﹤0.01% 2215
2026
Q1 		$4.62M Buy
+188,211
New +$6.16M ﹤0.01% 2118

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust's CSTL Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Castle Biosciences (CSTL) stake by 4.9% in Q2 2026, buying an estimated $207K and bringing the position to 197,494 shares worth $4.71M. The position accounts for ﹤0.01% of the portfolio, ranked #2215.

Vanguard Fiduciary Trust first reported a position in CSTL in Q1 2026 and has held it in 2 quarters since. 176 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Vanguard Fiduciary Trust held 197,494 shares of Castle Biosciences worth $4.71M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 9,283 Castle Biosciences shares in Q2 2026, an estimated $207K.
  • Castle Biosciences made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #2215 holding.
  • Vanguard Fiduciary Trust first reported a position in Castle Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 176 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.